In 2016, FDA Oncology approved five new molecular entities and 17 efficacy supplements, including six accelerated approvals, 17 priority reviews, and 11 approvals of breakthrough-designated therapies. The FDA also approved five companion diagnostics, including a liquid biopsy test. One new anti-PD-L1 antibody was approved, along with six supplementary approvals of anti-PD-1/PD-L1 antibodies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
Scientific Reports Open Access 25 September 2017
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicenter, phase 2 trial. Lancet 387, 1909–1920 (2016).
Blumenthal, G. M. & Pazdur, R. Response rate as an approval endpoint in oncology: back to the future. JAMA Oncol. 2, 780–781 (2016).
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
Ferris, R. L. et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 375, 1856–1867 (2016).
Roberts, A. W. et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 374, 311–322 (2016).
Kazandjian, D. et al. Benefit-risk summary of crizotinib for the treatment of patients with ROS1 alteration-positive, metastatic non-small cell lung cancer. Oncologist 21, 974–980 (2016).
Blumenthal, G. M., Mansfield, E. & Pazdur, R. Next-generation sequencing in oncology in the era of precision medicine. JAMA Oncol. 2, 13–14 (2016).
Sherman, R. E. et al. Real-world evidence — what is it and what can it tell us? N. Engl. J. Med. 375, 2293–2297 (2016).
National Cancer Institute. Cancer Moonshot Blue Ribbon Panel Report 2016. Cancer.gov https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative/blue-ribbon-panel (2016).
Pazdur, R. Leveraging the power of collaboration — FDA's new Oncology Center of Excellence. FDA Voice blog http://blogs.fda.gov/fdavoice/index.php/2016/06/leveraging-the-power-of-collaboration-fdas-new-oncology-center-of-excellence/ (2016).
Acknowledgements
The authors would like to thank Kirsten Goldberg from the Office of Hematology and Oncology Products, FDA for her assistance with editing this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Summary of FDA oncology drug approvals in 2016 (PDF 76 kb)
Related links
Rights and permissions
About this article
Cite this article
Blumenthal, G., Pazdur, R. Approvals in 2016: the march of the checkpoint inhibitors. Nat Rev Clin Oncol 14, 131–132 (2017). https://doi.org/10.1038/nrclinonc.2017.15
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2017.15
This article is cited by
-
Network Analysis of Drug–target Interactions: A Study on FDA-approved New Molecular Entities Between 2000 to 2015
Scientific Reports (2017)
-
Cancer Immunotherapies: Are They as Effective in the Elderly?
Drugs & Aging (2017)
